• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

All Healthy News

Clean Air. Pure Water. Healthy Home.

HEALTH BEGINS WITH:
Clean Air. Pure Water. Healthy Homes.

  • Home
  • About/Contact
  • HEALTH NEWS/TRENDS
  • CLEAN AIR
  • HEALTHY HOME
  • PURE WATER
  • Free Video Reveals

Full FDA Approval Granted to Pfizer-BioNTech COVID-19 Vaccine

August 23, 2021 by Staff Reporter

Pfizer-BioNTech COVID-19 Vaccine Receives Full FDA Approval – Consumer Health News

MONDAY, Aug. 23, 2021 (HealthDay News) — The U.S. Food and Drug Administration on Monday granted full approval for the Pfizer-BioNTech COVID-19 vaccine.

The vaccine will now be marketed as Comirnaty and is fully approved for the prevention of COVID-19 in individuals 16 years and older. The vaccine remains under emergency use authorization for individuals ages 12 to 15 years and for administration of a third dose in certain immunocompromised individuals.

“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated,” Acting FDA Commissioner Janet Woodcock, M.D., said in an agency press release. “Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S.”

The FDA decision to fully approve Comirnaty was based on a review of updated data from the clinical trial that supported the emergency use authorization. The updated data included a longer follow-up duration and a larger clinical trial population of 20,000 individuals who received the vaccine and 20,000 who received placebo. Based on the updated results, the vaccine was 91 percent effective in preventing COVID-19.

The review also included updated safety data on 22,000 people who received the vaccine and 22,000 who received placebo, more than half of whom were followed for at least four months.

The agency also conducted an evaluation of postauthorization safety surveillance data regarding the risks for myocarditis and pericarditis following receipt of the Pfizer-BioNTech COVID-19 vaccine. They found the data demonstrate increased risks, especially within the seven days following the second dose and with a higher risk among men younger than 40 years, in particular males ages 12 to 17 years. Data have shown symptom resolution in the majority of individuals, but some have required intensive care support.

The Comirnaty Prescribing Information includes a warning about these risks, but the agency notes that information is not yet available on potential long-term health outcomes. The FDA is requiring Pfizer-BioNTech to conduct postmarketing studies to further evaluate these risks.

 

Filed Under: HEALTH NEWS/TRENDS

Primary Sidebar

Reduce 99.9% of airborne SARS-CoV-2 Virus

Vollara ActivePure Technologies


News from the EPA

Ipswich concerns over air pollution links to dementia

Northern California fires bring smoke drifts to Mendocino County • The Mendocino Voice | Mendocino County, CAThe Mendocino Voice

The Recorder –  Ashley Muspratt: An alternative to gas, propane stoves

Austin American-Statesman Letters to the Editor: August 14, 2022

Wick Johnson: In Augusta, a triumph of vision and hope

Take needed precautions during a heatwave | News

B.C. man ordered to pay $13K for smoking in his strata unit

Breathe easier with Kaye Lifestyle Homes

Rover sniffs out answers to turn signal, smoking questions | News

Shasta College receives $3.3M to expand forest health programs – Red Bluff Daily News

Privacy Policy | Terms and Conditions | About/ Contact
Copyright © 2022 · ALL HEALTHY NEWS . Log in